Human inter-individual variability in metabolism and genotoxic response to zidovudine

Toxicology and Applied Pharmacology

Volumn 228, Issue 2, 2008, Pages 158-164

  Olivero, Ofelia A ^a   Ming, Jessica M ^a   Das, Shreyasi ^a   Vazquez, Irma L ^a   Richardson, Diana L ^b   Weston, Ainsley ^b   Poirier, Miriam C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

AZT; Nucleoside analogs; Thymidine kinase 1

Indexed keywords

BLEOMYCIN; DNA; THYMIDINE KINASE 1; ZIDOVUDINE;

ARTICLE; BREAST EPITHELIUM; CELL CYCLE S PHASE; CELL SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; GENOTOXICITY; HUMAN; HUMAN CELL; INDIVIDUALITY; METABOLISM; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; WESTERN BLOTTING;

APOPTOSIS; BLEOMYCIN; BLOTTING, WESTERN; CELL CYCLE; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; DNA; EPITHELIAL CELLS; FLOW CYTOMETRY; HUMANS; INTERPHASE; MAMMARY GLANDS, HUMAN; MICRONUCLEI, CHROMOSOME-DEFECTIVE; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTASE INHIBITORS; THYMIDINE KINASE; TIME FACTORS; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 41549090523     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2007.12.005     Document Type: Article

References (32)

1. Avramis V.I., Kwock R., Solorzano M.M., and Gomperts E. Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection. J. Acquir. Immune. Defic. Syndr. 6 (1993) 1287-1296
2. Cardo D.M., Culver D.H., Ciesielski C.A., Srivastava P.U., Marcus R., Abiteboul D., Heptonstall J., Ippolito G., Lot F., McKibben P.S., and Bell D.M. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N. Engl. J. Med. 337 (1997) 1485-1490
3. Centers for Disease Control and Prevention. NIOSH alert: request for assistance in preventing needlestick injuries in health care settings (1999), Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH). http://www.cdc.gov/niosh/2000-108.html http://www.cdc.gov/niosh/2000-108.html
4. Centers for Disease Control and Prevention. Advancing HIV Prevention: the science behind the new initiative (2003). http://www.cdc.gov/hiv/topics/prev http://www.cdc.gov/hiv/topics/prev
5. DHHS. Antiretroviral guidelines for adults and adolescents - a working group of the Office of AIDS Research Advisory Council (OARAC) (2006). http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. DHHS Panel
6. Divi R.L., Doerge D.R., Twaddle N.C., Shockley M.E., St. Claire M.C., Harbaugh J.W., Harbaugh S.W., and Poirier M.C. Metabolism and pharmacokinetics of the combination Zidovudine plus Lamivudine in the adult Erythrocebus patas monkey determined by liquid chromatography-tandem mass spectrometric analysis. Toxicology and Applied Pharmacology (2007). http://dx.doi.org/10.1016/j.taap.2007.09.007 http://dx.doi.org/10.1016/j.taap.2007.09.007
7. Diwan B.A., Riggs C.W., Logsdon D., Haines D.C., Olivero O.A., Rice J.M., Yuspa S.H., Poirier M.C., and Anderson L.M. Multiorgan transplacental and neonatal carcinogenicity of 3′-azido-3′-deoxythymidine in mice. Toxicol. Appl. Pharmacol. 15 (1999) 82-99
8. Escobar P.A., Olivero O.A., Wade N.A., Abrams E.J., Nesel C.J., Ness R.B., Day R.D., Day B.W., Meng Q., O'Neill J.P., Walker D.M., Poirier M.C., Walker V.E., and Bigbee W.L. Genotoxicity assessed by the comet and GPA assays following in vitro exposure of human lymphoblastoid cells (H9) or perinatal exposure of mother-child pairs to AZT or AZT-3TC. Environ. Mol. Mutagen. 48 (2007) 330-343
9. Fletcher C.V. Pharmacologic considerations for therapeutic success with antiretroviral agents. Ann. Pharmacother. 33 (1999) 989-995
10. Furman P.A., Fyfe J.A., St Clair M.H., Weinhold K., Rideout J.L., Freeman G.A., Lehrman S.N., Bolognesi D.P., Broder S., Mitsuya H., and Barry D.A. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proceedings of the National Academy of Sciences of the United States of America 83 (1986) 8333-8337
11. IARC. Monographs on the evaluation of carcinogenic risks to humans. Some antiviral and antineoplastic drugs, and other pharmaceutical agents. World Health Organization vol. 76 (2000), International Agency for Research on Cancer, Lyon, France 73-127
12. Jacobsson B., Britton S., He Q., Karlsson A., and Eriksson S. Decreased thymidine kinase levels in peripheral blood cells from HIV-seropositive individuals: implications for zidovudine metabolism. AIDS Res. Hum. Retroviruses 11 (1995) 805-811
13. Jacobsson B., Britton S., Tornevik Y., and Eriksson S. Decrease in thymidylate kinase activity in peripheral blood mononuclear cells from HIV-infected individuals. Biochem. Pharmacol. 56 (1998) 389-395
14. Keshava C., Whipkey D., and Weston A. Transcriptional signatures of environmentally relevant exposures in normal human mammary epithelial cells: benzo[a]pyrene. Cancer Letters 221 (2005) 201-211
15. Moodley J., Moodley D., Pillay K., Coovadia H., Saba J., van Leeuwen R., Goodwin C., Harrigan P.R., Moore K.H., Stone C., Plumb R., and Johnson M.A. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J. Infect. Dis. 178 (1998) 1327-1333
16. Murphy P.D., Kidd J.R., Castiglione C.M., Lin P.F., Ruddle F.H., and Kidd K.K. A frequent polymorphism for the cytosolic thymidine kinase gene, TK1, (17q21-q22) detected by the enzyme TaqI. Nucleic Acids Research 14 (1986) 4381
17. Murphy P.D., Lin P.F., Ruddle F.H., and Kidd K.K. A second useful polymorphism for the cytosolic thymidine kinase gene (TK1) with the enzyme BstEII which will allow haplotying at this locus on chromosome 17 (q21-q22). Nucleic Acids Research 15 (1987) 7212
18. NTP. Toxicology and carcinogenesis studies of AZT (1996), National Toxicology Program, Research Triangle Park, NC
19. O'Sullivan M.J., Boyer P.J., Scott G.B., Parks W.P., Weller S., Blum M.R., Balsley J., and Bryson Y.J. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. Am. J. Obstet. Gynecol. 168 (1993) 1510-1516
20. Olivero O.A. Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors. Environ. Mol. Mutagen. 48 (2007) 215-223
21. Olivero O.A., Beland F.A., and Poirier M.C. Immunofluorescent localization and quantitation of 3′-azido-2′,3′-dideoxythymidine (AZT) incorporated into chromosomal DNA of human, hamster and mouse cell lines. International Journal of Oncology 4 (1994) 49-54
22. Olivero O.A., Anderson L.M., Diwan B.A., Haines D.C., Harbaugh S.W., Moskal T.J., Jones A.B., Rice J.M., Riggs C.W., Logsdon D., Yuspa S.H., and Poirier M.C. Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J. Natl. Cancer Inst. 89 (1997) 1602-1608
23. Olivero O.A., Shearer G.M., Chougnet C.A., Kovacs A.A., Landay A.L., Baker R., Stek A.M., Khoury M.M., Proia L.A., Kessler H.A., Sha B.E., Tarone R.E., and Poirier M.C. Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. AIDS 13 (1999) 919-925
24. Olivero O.A., Fernandez J.J., Antiochos B.B., Wagner J.L., St Claire M.E., and Poirier M.C. Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys. J. Acquir. Immune. Defic. Syndr. 29 (2002) 323-329
25. Olivero O.A., Tejera A.M., Fernandez J.J., Taylor B.J., Das S., Divi R.L., and Poirier M.C. Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis 20 (2005) 139-146
26. Patterson T.A., Binienda Z.K., Lipe G.W., Gillam M.P., Slikker Jr. W., and Sandberg J.A. Transplacental pharmacokinetics and fetal distribution of azidothymidine, its glucuronide, and phosphorylated metabolites in late- term rhesus macaques after maternal infusion. Drug Metab. Dispos. 25 (1997) 453-459
27. Poirier M.C., Olivero O.A., Walker D.M., and Walker V.E. Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicol. Appl. Pharmacol. 199 (2004) 151-161
28. Sambrook J., Fritsch E.F., and Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. (1989), Cold Spring Harbor Laboratory Press, New York
29. Turriziani O., and Antonelli G. Host factors and efficacy of antiretroviral treatment. New Microbiol. 27 (2004) 63-69
30. Vazquez I.L., Olivero O.A., and Poirier M.C. Altered AZT metabolism may induce cellular drug resistance in human cells. Environmental and Molecular Mutagenesis 44 (2004) 234 Abstract # 186
31. Walker D.M., Malarkey D.E., Seilkop S.K., Ruecker F.A., Funk K.A., Wolfe M.J., Treanor C.P., Foley J.F., Hahn F.F., Hardisty J.F., and Walker V.E. Transplacental carcinogenicity of 3′-azido-3′-deoxythymidine in B6C3F1 mice and F344 rats. Environ. Mol. Mutagen. 48 (2007) 283-298
32. Wu S., Liu X., Solorzano M.M., Kwock R., and Avramis V.I. Development of zidovudine (AZT) resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5′ end of human TK gene. J. Acquir. Immune. Defic. Syndr. Hum Retrovirol. 8 (1995) 1-9